Trevi Therapeutics, Inc.
NASDAQTrevi Therapeutics enters its May 7 earnings release with a meaningful short base still in place, even as the stock has rebounded sharply and the lending market suggests bears are not pressing harder. Short sellers remain committed. At 12.3% of the free float, short interest is elevated for a small-cap biotech — and it has edged up 3.2% over the past week. That said, the wider…
Snapshot as of 6 May 2026
Trevi Therapeutics enters its May 7 earnings release with a meaningful short base still in place, even as the stock has rebounded sharply and the lending market suggests bears are not pressing harder. Short sellers…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TRVI — free to start on ORTEX.
Sign up for free →Open TRVI on ORTEX